Small Masses Near a BioZorb Marker After DCIS Treatment Were Fat Necrosis
This breast cancer diagnosis at a glance
- Subtype
- Invasive Ductal Carcinoma
- Biomarkers
- ER-positive.
- Sex
- Female
- Treatment
- surgery, radiation and surveillance
- Outcome
- Care Ongoing
Treatment course, step by step
- Left breast lumpectomy with BioZorb placement was performed.
- Postoperative radiation was completed.
- Mammographic surveillance was performed every six months.
- Small masses detected near the BioZorb site at three years were biopsied and showed fat necrosis.
What happened, in summary
A 55-year-old woman had a 1.1 cm mass detected at the 11 o’clock position of the left breast. Biopsy showed grade II ductal carcinoma in situ with micropapillary and cribriform features, and the lesion was ER-positive.
She underwent lumpectomy with placement of a BioZorb marker, followed by postoperative radiation. Mammographic surveillance was performed every six months.
At the three-year examination, imaging showed several small masses developing next to the BioZorb site. New masses near a previous DCIS treatment bed can raise concern for recurrent disease, even when they appear related to surgery or radiation. Stereotactic biopsy was therefore performed.
The tissue showed fat necrosis, and the pathology was considered consistent with the imaging findings. The masses represented a benign treatment-related change rather than confirmed recurrent DCIS. Her case illustrates how postoperative healing around a BioZorb device can evolve over several years and lead to additional biopsy during routine surveillance.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- ER Positive Breast Cancer 242 stories
- Lumpectomy for Breast Cancer 208 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer